Drug firms Lupin Ltd and Aurobindo Pharma today said they have received US health regulator's approval to sell generic Combivir tablets, used in treating HIV infection, in the American market.
Lupin has rallied 6% to Rs 544 in otherwise weak market in noon deals, on reports that the drug maker is expected to soon launch its generic version of the anti-HIV drug, Combivir, in the United States.
Drug maker Lupin Ltd today said its consolidated net profit declined by 29.54% to Rs 161.19 crore for the fourth quarter ended March 31, 2012, due to higher tax expenses.
Pharmaceutical firm Lupin is setting up a new manufacturing plant at the MIHAN special economic zone (SEZ) in Nagpur, entailing an investment of Rs 400 crore over a period of five years.
Drug firm Lupin today said, it has resumed sales of generic version of Shionogi's Fortamet tablets, used in treating diabetes, in the American market after getting clearance from a US Court.
Three Indian drug majors, Lupin, Dr Reddy's, Sun Pharma have got approvals from the US health regulator to sell generic quetiapine fumarate tablets, used in treating mental disorders, in the American market.
Drug firm Lupin today said it had received approval from the US health regulator for its generic Ziprasidone Hydrochloride capsules, used for treating mental disorders, in the American market.
Drug maker Lupin today said it has reached a patent litigation settlement agreement with US-based firms Santarus Inc and Depomed Inc involving diabetes drug Glumetza.
Mumbai-based pharmaceutical company Lupin Limited is planning to invest $20 million in setting up a new manufacturing facility in Pune, according to company president Cyrus Karkaria.
Drug firm Lupin today said it has received approval from the US health regulator for its Metformin Hydrochloride Extended Release tablets, used in treating diabetes.
Drug firm Lupin on Tuesday said its consolidated net profit rose 4.95 per cent to Rs 235 crore in the quarter ended December 31, on the back of robust sales in the US, India and Japan, the company's key markets.
Drug firm Lupin today said its consolidated net profit rose by 4.95% to Rs 235.1 crore for the third quarter ended December 31, 2011, over the same period last fiscal.
From zero revenues eight years ago, Lupin has posted Rs 621 crore in sales last year-that too in a country regarded as one of the toughest markets in the world for generics.
The pharmaceutical industry will remember 2011 as a year in which the government sought more to exercise more control over the business — be it big ticket acquisitions of domestic firms by MNCs or price controls on drugs.
Drug maker Lupin is eyeing a jump of over 80% in its revenues to $300 million (Rs 1,557 crore) from the Japanese market in the next two years on the back of its enhanced presence in the country.
